patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_816644 | REC_0014501 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 30 | 5.7 | 65 | female | 0 | 17 | 6.6 | 1 | pembrolizumab 200 mg q3w | 23.7 | true | MSS | 2026-03-15T05:36:00.821382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397628 | REC_0014502 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 7.7 | 63 | male | 0 | 10 | 7.6 | 8 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:36:00.821750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669159 | REC_0014503 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 7 | 77 | female | 1 | 56 | 3.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 14 | false | MSS | 2026-03-15T05:36:00.822100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488105 | REC_0014504 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 16.6 | 90 | female | 2 | 17 | 5.9 | 4 | pembrolizumab 200 mg q3w | 5 | true | MSS | 2026-03-15T05:36:00.822500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937575 | REC_0014505 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 11.5 | 67 | female | 1 | 14 | 4.6 | 1 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:36:00.822856+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855744 | REC_0014506 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 10.2 | 45 | female | 0 | 10 | 5.9 | 1 | osimertinib 80 mg daily | 23.2 | false | MSI-H | 2026-03-15T05:36:00.823217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_403810 | REC_0014507 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.4 | 75 | male | 1 | 15 | 5 | 7 | pembrolizumab 200 mg q3w | 11.7 | true | MSS | 2026-03-15T05:36:00.823565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872778 | REC_0014508 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.4 | 75 | female | 1 | 13 | 4.7 | 5 | osimertinib 80 mg daily | 9.7 | true | MSI-H | 2026-03-15T05:36:00.823900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161908 | REC_0014509 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 12.7 | 61 | male | 1 | 9 | 5 | 1 | osimertinib 80 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:36:00.824459+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_894412 | REC_0014510 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 17 | 64 | female | 0 | 17 | 4.9 | 5 | osimertinib 80 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:36:00.824857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232858 | REC_0014511 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 6.6 | 76 | female | 0 | 81 | 5.9 | 7 | pembrolizumab 200 mg q3w | 11.1 | false | MSS | 2026-03-15T05:36:00.825189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852610 | REC_0014512 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 12.9 | 69 | male | 0 | 13 | 3.6 | 1 | osimertinib 80 mg daily | 18 | true | MSI-H | 2026-03-15T05:36:00.825631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640369 | REC_0014513 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.4 | 70 | female | 1 | 24 | 6.6 | 5 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:36:00.825992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941258 | REC_0014514 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 8 | 72 | male | 0 | 38 | 5.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 15.9 | false | MSS | 2026-03-15T05:36:00.826357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169067 | REC_0014515 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 13.3 | 68 | male | 0 | 20 | 4.5 | 2 | osimertinib 80 mg daily | 21.7 | false | MSI-H | 2026-03-15T05:36:00.826742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970062 | REC_0014516 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 7.7 | 74 | female | 2 | 15 | 6.1 | 6 | entrectinib 600 mg daily | 6.1 | true | MSS | 2026-03-15T05:36:00.827090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500288 | REC_0014517 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.2 | 65 | male | 1 | 50 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 17.6 | false | MSS | 2026-03-15T05:36:00.827439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607357 | REC_0014518 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 9.6 | 71 | female | 1 | 12 | 6.2 | 1 | alectinib 600 mg BID | 33.5 | true | MSS | 2026-03-15T05:36:00.827763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166863 | REC_0014519 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 3.9 | 66 | male | 1 | 13 | 5.7 | 5 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:36:00.828148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303855 | REC_0014520 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 13.2 | 72 | female | 2 | 12 | 3.9 | 6 | entrectinib 600 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:36:00.828530+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397289 | REC_0014521 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 8.1 | 74 | female | 2 | 24 | 5 | 0 | sotorasib 960 mg daily | 16.3 | false | MSS | 2026-03-15T05:36:00.828879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637543 | REC_0014522 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.9 | 71 | female | 0 | 11 | 4.5 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.829378+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771417 | REC_0014523 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 5.6 | 63 | male | 1 | 46 | 5.2 | 3 | carboplatin + paclitaxel + pembrolizumab | 7.1 | true | MSS | 2026-03-15T05:36:00.829806+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_645689 | REC_0014524 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 35 | 9.7 | 67 | female | 1 | 18 | 5.7 | 2 | osimertinib 80 mg daily | 10.8 | false | MSS | 2026-03-15T05:36:00.830205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757591 | REC_0014525 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 13 | 65 | female | 0 | 5 | 5.3 | 2 | entrectinib 600 mg daily | 15.6 | true | MSI-H | 2026-03-15T05:36:00.830571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496739 | REC_0014526 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 38 | 11 | 77 | male | 2 | 12 | 5.7 | 5 | alectinib 600 mg BID | 7.3 | true | MSS | 2026-03-15T05:36:00.830915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697939 | REC_0014527 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 7 | 62 | male | 0 | 70 | 6.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 40.3 | false | MSS | 2026-03-15T05:36:00.831256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957698 | REC_0014528 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 14.8 | 58 | male | 1 | 24 | 4.5 | 5 | alectinib 600 mg BID | 18.3 | false | MSI-H | 2026-03-15T05:36:00.833010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874254 | REC_0014529 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 34 | 4.3 | 68 | female | 0 | 15 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:36:00.833906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_100992 | REC_0014530 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 11.1 | 65 | female | 0 | 11 | 4.5 | 1 | pembrolizumab 200 mg q3w | 24.2 | false | MSI-H | 2026-03-15T05:36:00.834569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_752354 | REC_0014531 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 14.7 | 77 | female | 2 | 24 | 3 | 1 | sotorasib 960 mg daily | 16.5 | true | MSS | 2026-03-15T05:36:00.836272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535662 | REC_0014532 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 14.3 | 79 | female | 2 | 14 | 5.6 | 7 | alectinib 600 mg BID | 17.2 | true | MSI-H | 2026-03-15T05:36:00.836820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583151 | REC_0014533 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 8 | 64 | male | 0 | 12 | 5.5 | 8 | osimertinib 80 mg daily | 7.7 | true | MSS | 2026-03-15T05:36:00.837202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905156 | REC_0014534 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 11.8 | 73 | female | 1 | 26 | 5.7 | 4 | entrectinib 600 mg daily | 13.5 | true | MSS | 2026-03-15T05:36:00.837645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919606 | REC_0014535 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 11 | 62 | female | 1 | 22 | 7.1 | 1 | sotorasib 960 mg daily | 18.1 | false | MSI-H | 2026-03-15T05:36:00.838180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_653081 | REC_0014536 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 17.8 | 50 | female | 0 | 15 | 4.9 | 4 | entrectinib 600 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:36:00.838578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543454 | REC_0014537 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 34 | 4.7 | 77 | female | 2 | 18 | 6.3 | 1 | sotorasib 960 mg daily | 7.3 | true | MSS | 2026-03-15T05:36:00.838934+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684770 | REC_0014538 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.9 | 59 | male | 1 | 11 | 5.1 | 7 | sotorasib 960 mg daily | 15.5 | true | MSS | 2026-03-15T05:36:00.839292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300252 | REC_0014539 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 20 | 8.4 | 62 | male | 0 | 17 | 9.4 | 0 | pembrolizumab 200 mg q3w | 41 | false | MSS | 2026-03-15T05:36:00.839676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764460 | REC_0014540 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 7.2 | 82 | female | 0 | 21 | 5 | 4 | pembrolizumab 200 mg q3w | 11.8 | true | MSS | 2026-03-15T05:36:00.840002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573540 | REC_0014541 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 12.3 | 68 | female | 1 | 3 | 3.1 | 2 | entrectinib 600 mg daily | 16.8 | false | MSI-H | 2026-03-15T05:36:00.840438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805013 | REC_0014542 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 12.1 | 66 | female | 0 | 8 | 6 | 2 | osimertinib 80 mg daily | 29.2 | false | MSI-H | 2026-03-15T05:36:00.840781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_928789 | REC_0014543 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 14.9 | 65 | male | 0 | 13 | 6.4 | 2 | osimertinib 80 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:36:00.841113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655383 | REC_0014544 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.2 | 78 | male | 2 | 6 | 4.8 | 7 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:36:00.841439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202752 | REC_0014545 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 12.2 | 59 | female | 0 | 20 | 5.2 | 1 | sotorasib 960 mg daily | 22.9 | true | MSI-H | 2026-03-15T05:36:00.841752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812356 | REC_0014546 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 19 | 7.2 | 62 | male | 1 | 4 | 6.9 | 0 | pembrolizumab 200 mg q3w | 31.1 | true | MSS | 2026-03-15T05:36:00.842065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363154 | REC_0014547 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14 | 75 | female | 0 | 13 | 5.4 | 4 | osimertinib 80 mg daily | 5.5 | false | MSS | 2026-03-15T05:36:00.842420+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850641 | REC_0014548 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 4.5 | 67 | female | 0 | 17 | 3.2 | 7 | sotorasib 960 mg daily | 6.4 | true | MSS | 2026-03-15T05:36:00.842863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230612 | REC_0014549 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.3 | 66 | male | 0 | 13 | 5.9 | 4 | entrectinib 600 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:00.843226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_148331 | REC_0014550 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9.3 | 71 | female | 0 | 12 | 5.4 | 5 | sotorasib 960 mg daily | 17.7 | true | MSS | 2026-03-15T05:36:00.843578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662536 | REC_0014551 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 16.8 | 69 | female | 0 | 10 | 5.2 | 5 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:36:00.843947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445190 | REC_0014552 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 11.3 | 65 | female | 1 | 8 | 6.5 | 4 | entrectinib 600 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:36:00.844418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977479 | REC_0014553 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 8.9 | 66 | female | 0 | 8 | 4.2 | 5 | entrectinib 600 mg daily | 14.9 | true | MSS | 2026-03-15T05:36:00.844748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425492 | REC_0014554 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.4 | 71 | female | 2 | 34 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:36:00.845075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_286967 | REC_0014555 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 8.3 | 67 | female | 1 | 14 | 4.9 | 5 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:36:00.845427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639483 | REC_0014556 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 10.4 | 52 | female | 0 | 23 | 4.5 | 4 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:36:00.845768+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_122766 | REC_0014557 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 13.6 | 59 | male | 0 | 15 | 4.5 | 2 | osimertinib 80 mg daily | 20 | false | MSI-H | 2026-03-15T05:36:00.846085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517804 | REC_0014558 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 14.4 | 70 | female | 2 | 11 | 6.4 | 4 | pembrolizumab 200 mg q3w | 8.2 | true | MSS | 2026-03-15T05:36:00.846390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243850 | REC_0014559 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.4 | 64 | female | 0 | 20 | 4.7 | 2 | entrectinib 600 mg daily | 25.2 | true | MSS | 2026-03-15T05:36:00.846695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819904 | REC_0014560 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 14.9 | 71 | female | 1 | 5 | 6.9 | 4 | osimertinib 80 mg daily | 10.1 | false | MSS | 2026-03-15T05:36:00.847039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_425626 | REC_0014561 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 2.4 | 66 | female | 0 | 27 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.6 | false | MSS | 2026-03-15T05:36:00.847496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278687 | REC_0014562 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.1 | 66 | female | 0 | 14 | 6.9 | 7 | alectinib 600 mg BID | 7.1 | true | MSS | 2026-03-15T05:36:00.847829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679354 | REC_0014563 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 10.7 | 69 | female | 0 | 22 | 6.7 | 1 | pembrolizumab 200 mg q3w | 19.4 | false | MSS | 2026-03-15T05:36:00.848188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705027 | REC_0014564 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 13.6 | 58 | male | 0 | 10 | 4.5 | 3 | alectinib 600 mg BID | 19.2 | true | MSS | 2026-03-15T05:36:00.848567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800543 | REC_0014565 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 7.4 | 81 | male | 1 | 16 | 6.6 | 7 | pembrolizumab 200 mg q3w | 14.3 | true | MSS | 2026-03-15T05:36:00.848922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336995 | REC_0014566 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 15.2 | 58 | male | 0 | 7 | 3.1 | 1 | alectinib 600 mg BID | 23.8 | true | MSI-H | 2026-03-15T05:36:00.849230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676956 | REC_0014567 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 7.3 | 69 | female | 1 | 5 | 4.7 | 3 | alectinib 600 mg BID | 10.3 | true | MSS | 2026-03-15T05:36:00.849512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633224 | REC_0014568 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 13.4 | 75 | male | 1 | 15 | 6 | 6 | osimertinib 80 mg daily | 16.5 | false | MSS | 2026-03-15T05:36:00.849818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195788 | REC_0014569 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 11.2 | 66 | male | 1 | 6 | 6.4 | 1 | osimertinib 80 mg daily | 27.3 | true | MSI-H | 2026-03-15T05:36:00.850178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465463 | REC_0014570 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 9.1 | 73 | female | 3 | 39 | 5.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.1 | false | MSS | 2026-03-15T05:36:00.850487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336833 | REC_0014571 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 5.9 | 55 | male | 0 | 7 | 5.2 | 1 | pembrolizumab 200 mg q3w | 20.3 | true | MSS | 2026-03-15T05:36:00.850807+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780658 | REC_0014572 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 9.6 | 72 | female | 2 | 13 | 4.8 | 2 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:36:00.851103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_815774 | REC_0014573 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 3.6 | 68 | female | 0 | 34 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 30.7 | false | MSS | 2026-03-15T05:36:00.851394+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_180959 | REC_0014574 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 24 | 7.2 | 71 | female | 2 | 10 | 3.5 | 2 | pembrolizumab 200 mg q3w | 25.6 | true | MSS | 2026-03-15T05:36:00.851849+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_187398 | REC_0014575 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.4 | 66 | male | 1 | 52 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:36:00.852263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700485 | REC_0014576 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 13.7 | 77 | female | 1 | 16 | 5.8 | 7 | sotorasib 960 mg daily | 8.8 | false | MSS | 2026-03-15T05:36:00.852565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461342 | REC_0014577 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12.3 | 60 | female | 0 | 23 | 5.2 | 2 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:00.852848+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652296 | REC_0014578 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11.8 | 61 | male | 1 | 7 | 4.8 | 4 | osimertinib 80 mg daily | 12 | false | MSS | 2026-03-15T05:36:00.853129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974594 | REC_0014579 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.4 | 70 | female | 1 | 12 | 4.5 | 7 | entrectinib 600 mg daily | 9.1 | true | MSS | 2026-03-15T05:36:00.853415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383813 | REC_0014580 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 15.8 | 72 | female | 1 | 16 | 8.4 | 6 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:36:00.853730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845771 | REC_0014581 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.8 | 73 | female | 1 | 24 | 4.4 | 6 | alectinib 600 mg BID | 9.4 | false | MSS | 2026-03-15T05:36:00.854048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_121572 | REC_0014582 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.2 | 68 | female | 0 | 12 | 3.6 | 2 | alectinib 600 mg BID | 11.9 | false | MSI-H | 2026-03-15T05:36:00.854362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935614 | REC_0014583 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.2 | 69 | female | 0 | 2 | 5.2 | 3 | pembrolizumab 200 mg q3w | 8.2 | false | MSS | 2026-03-15T05:36:00.854663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298910 | REC_0014584 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.8 | 71 | female | 1 | 14 | 3 | 6 | osimertinib 80 mg daily | 6.2 | false | MSS | 2026-03-15T05:36:00.855046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700556 | REC_0014585 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10.5 | 56 | male | 0 | 8 | 5.3 | 5 | entrectinib 600 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:00.855419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137340 | REC_0014586 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 9.1 | 60 | male | 1 | 44 | 7.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.3 | false | MSS | 2026-03-15T05:36:00.855727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311755 | REC_0014587 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 10.2 | 62 | female | 0 | 12 | 5.7 | 5 | entrectinib 600 mg daily | 10 | true | MSS | 2026-03-15T05:36:00.856295+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368879 | REC_0014588 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 19.4 | 65 | female | 1 | 16 | 4.4 | 6 | entrectinib 600 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:36:00.856678+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126075 | REC_0014589 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 20.3 | 73 | female | 2 | 14 | 6.4 | 2 | alectinib 600 mg BID | 16.7 | false | MSI-H | 2026-03-15T05:36:00.857058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903461 | REC_0014590 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 4.8 | 65 | male | 1 | 12 | 5.1 | 1 | pembrolizumab 200 mg q3w | 26.7 | false | MSS | 2026-03-15T05:36:00.857412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357904 | REC_0014591 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 12.6 | 55 | male | 0 | 13 | 5.4 | 1 | alectinib 600 mg BID | 20.1 | false | MSI-H | 2026-03-15T05:36:00.857742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207746 | REC_0014592 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 17.6 | 64 | male | 0 | 11 | 8.1 | 5 | pembrolizumab 200 mg q3w | 9.5 | false | MSI-H | 2026-03-15T05:36:00.858058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758092 | REC_0014593 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 13.2 | 65 | female | 1 | 10 | 6.4 | 3 | alectinib 600 mg BID | 12.4 | true | MSS | 2026-03-15T05:36:00.858384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158480 | REC_0014594 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 9.7 | 73 | female | 1 | 11 | 2.7 | 7 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.858702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_856719 | REC_0014595 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 5.8 | 68 | female | 1 | 2 | 5.3 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:00.859069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792993 | REC_0014596 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.5 | 45 | male | 0 | 24 | 6.5 | 6 | entrectinib 600 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:36:00.859388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466765 | REC_0014597 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 13.1 | 66 | female | 0 | 13 | 3.5 | 7 | osimertinib 80 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:36:00.859711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277232 | REC_0014598 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 16.6 | 63 | female | 0 | 17 | 4.4 | 8 | entrectinib 600 mg daily | 11.4 | false | MSS | 2026-03-15T05:36:00.860061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688585 | REC_0014599 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 3.9 | 69 | female | 1 | 26 | 6.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:36:00.860503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633761 | REC_0014600 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 19.5 | 71 | female | 1 | 22 | 6.2 | 6 | osimertinib 80 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:36:00.861015+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.